AssetMark’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.6K Buy
917
+184
+25% +$2.51K ﹤0.01% 2428
2026
Q2
$9.9K Buy
733
+711
+3,232% +$8.5K ﹤0.01% 2450
2026
Q1
$134 Sell
22
-4
-15% -$30 ﹤0.01% 3361
2025
Q4
$186 Sell
26
-118
-82% -$932 ﹤0.01% 3263
2025
Q3
$1.54K Buy
144
+84
+140% +$824 ﹤0.01% 2684
2025
Q2
$581 Sell
60
-299
-83% -$3.08K ﹤0.01% 2718
2025
Q1
$5.35K Buy
359
+237
+194% +$3.64K ﹤0.01% 1984
2024
Q4
$1.82K Sell
122
-50
-29% -$815 ﹤0.01% 2138
2024
Q3
$3.29K Buy
172
+113
+192% +$2.34K ﹤0.01% 1789
2024
Q2
$1.22K Buy
59
+38
+181% +$755 ﹤0.01% 1827
2024
Q1
$395 Sell
21
-33
-61% -$566 ﹤0.01% 1743
2023
Q4
$779 Buy
54
+11
+26% +$150 ﹤0.01% 1647
2023
Q3
$746 Buy
43
+7
+19% +$146 ﹤0.01% 1549
2023
Q2
$749 Hold
36
– – ﹤0.01% 1484
2023
Q1
$847 Sell
36
-1
-3% -$27 ﹤0.01% 1457
2022
Q4
$1.03K Hold
37
– – ﹤0.01% 1483
2022
Q3
$1K Sell
37
-20
-35% -$604 ﹤0.01% 1466
2022
Q2
$2K Hold
57
– – ﹤0.01% 1381
2022
Q1
$2K Sell
57
-40
-41% -$1.37K ﹤0.01% 1432
2021
Q4
$3K Buy
97
+21
+28% +$684 ﹤0.01% 1328
2021
Q3
$2K Sell
76
-332
-81% -$10.6K ﹤0.01% 1281
2021
Q2
$12K Buy
+408
New +$13.4K ﹤0.01% 966

Other funds holding OGN

AssetMark's OGN Position: Q3 2026 in Review

AssetMark increased its Organon & Co (OGN) stake by 25% in Q3 2026, buying an estimated $2.51K and bringing the position to 917 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

AssetMark first reported a position in OGN in Q2 2021 and has held it in 22 quarters since. 516 funds tracked by Wall St. Rank hold OGN as of Q3 2026.

  • AssetMark held 917 shares of Organon & Co worth $12.6K as of Q3 2026.
  • AssetMark bought 184 Organon & Co shares in Q3 2026, an estimated $2.51K.
  • Organon & Co made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2428 holding.
  • AssetMark first reported a position in Organon & Co in Q2 2021 and has held it in 22 quarters since.
  • 516 funds tracked by Wall St. Rank held Organon & Co as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.